$1.37
4.18%
Nasdaq, Oct 02, 04:00 pm EDT. Closed.
ISIN
US02262M3088
Symbol
ALZN

Alzamend Neuro Inc Stock price

$1.37
-0.33 19.41% 1M
+0.37 37.01% 6M
-0.45 24.73% YTD
-1.10 44.53% 1Y
-291.45 99.53% 3Y
-3,981.13 99.97% 5Y
-18,223.63 99.99% 10Y
-18,223.63 99.99% 20Y
Nasdaq, Closing price Fri, Oct 02 2026
+0.06 4.18%
ISIN
US02262M3088
Symbol
ALZN
Industry

Is Alzamend Neuro Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
$6.6m
Enterprise Value
$-980.0k
Net debt
positive
Cash
$7.6m
Shares outstanding
4.8m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
0.1 | 0.1
P/B
1.1
Financial Health
Equity Ratio
35.3%
Return on Equity
-1,196.5%
ROCE
-156.8%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$700.0k | -
SBC as % of FCF
-
SBC Growth 1Y
141.4%
Share Count Growth 1Y
53.8%
Shareholder Yield
-53.8%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-9.0m
EBIT
$-9.1m
Net Income
$-9.1m
Free Cash Flow | ex SBC
$-6.8m | $-7.5m
Growth
Revenue | estimate
- | -
EBITDA
-45.5%
EBIT
-45.8%
Net Income
-32.1%
Free Cash Flow
13.2%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-2.0
FCF per Share
$-1.4
Short interest
2.6%
Employees
5
Rev per Employee
$0.0

Alzamend Neuro Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Alzamend Neuro Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Alzamend Neuro Inc forecast:

Buy
86%
Hold
14%

Financial data from Alzamend Neuro Inc

Jul '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.12 6.12
86% 86%
-
- Research and Development Expense 2.97 2.97
1% 1%
-
-8.98 -8.98
46% 46%
-
- Depreciation and Amortization 0.11 0.11
57% 57%
-
EBIT (Operating Income) EBIT -9.09 -9.09
46% 46%
-
Net Profit -9.10 -9.10
32% 32%
-

In millions USD.

Don't miss a Thing! We will send you all news about Alzamend Neuro Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alzamend Neuro Inc Stock News

Neutral
PRNewsWire
●
about one month ago
Neuroscience 2026, the annual meeting of the Society for Neuroscience, will be held November 14–18, 2026   in Washington, DC Presentation Title: Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase 1/2A Clinical Trial ATLANTA, Aug. 20, 2026 /PRNewswire/ -- Alzamend Neuro, Inc.  (Nasdaq: ALZN) ("Alz...
Neutral
PRNewsWire
●
about 2 months ago
ISMRM Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR will be held September 28 – October 1, 2026   at the Universitat Oberta de Catalunya (UOC) in Barcelona, Spain Presentation will report first-of-its-kind pharmacokinetic imaging results from Phase 1/2A trial of AL001, Alzamend's novel organic lithium drug candidate, in healthy human subjects ATLANTA, Aug. 18, 2026 /PRNewsw...
Neutral
PRNewsWire
●
2 months ago
Company received $7.5 million in gross proceeds from the initial tranche of Series D Convertible Preferred Stock Agreement provides for up to $17.5 million in additional funding through subsequent tranche closings to support Alzamend's clinical programs and working capital needs ATLANTA, Aug. 4, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceu...
More Alzamend Neuro Inc News

Company Profile

Alzamend Neuro, Inc. is a preclinical stage biopharmaceutical company, which engages in the manufacture of pharmaceutical products. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Tampa, FL.

Head office United States
CEO Mr. Jackman
Employees 5
Founded 2016
Website alzamend.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today